Cytek Biosciences Inc (CTKB)
Debt-to-capital ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||
|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 393,064 | 415,524 | 424,179 | 423,460 | 425,546 | 416,509 | 411,129 | 407,442 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $393,064K)
= 0.00
The debt-to-capital ratio for Cytek Biosciences Inc has consistently been 0.00 for the past 11 quarters, indicating that the company has not utilized any debt to finance its operations relative to its total capital structure during this period. A debt-to-capital ratio of 0.00 implies that the company's total debt is negligible or non-existent compared to its total capital, which includes both debt and equity. This could suggest that Cytek Biosciences has been relying primarily on equity financing or internally generated funds to support its business activities, rather than taking on debt obligations. While a low debt-to-capital ratio can signal a strong financial position and lower financial risk, it may also indicate that the company is not leveraging debt as a potential source of capital for growth or expansion. Analysts may want to further investigate the reasons behind Cytek Biosciences' consistent zero debt-to-capital ratio to understand its capital structure strategy and implications for future financial performance and growth opportunities.
Peer comparison
Dec 31, 2023